迈威生物：阿达木单抗注射液在印度尼西亚获批上市

Core Viewpoint - Maiwei Biotech announced that its adalimumab injection 9MW0113 (domestic brand name: Junmaikang®) has received registration approval from the Indonesian Food and Drug Authority (BPOM), marking it as the first adalimumab biosimilar independently developed in China to gain such approval in Indonesia [1] Group 1 - 9MW0113 was co-developed by Maiwei Biotech and Junshi Bioscience [1] - The product has been formally partnered in over ten countries, indicating a strong international collaboration strategy [1] - Registration application documents have been submitted to multiple countries, including Jordan and Peru, showcasing the company's global expansion efforts [1]